Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for various dermatological conditions and related diseases
The company leverages its proprietary drug delivery systems and advanced therapeutics to address unmet medical needs, particularly in the treatment of skin disorders such as atopic dermatitis and psoriasis. Hoth's research is centered on bringing new solutions to patients by improving the efficacy and safety of existing treatments, thus enhancing the quality of life for those affected by challenging skin conditions.
Hoth Therapeutics reveals preclinical findings on HT-ALZ, a potential Alzheimer's therapeutic targeting the Substance P/Neurokinin 1 Receptor pathway. HT-ALZ exhibits significant reductions in soluble Aβ levels, alleviates anxiety, and enhances cognitive function in preclinical models.
